Bengaluru: biocon is betting big on new product launches in its geneerics and biosimilars Portfolios, which are expected to fuel its expansion in the next 2-3 years. The company is leveraging the Viatris Acquisition To provide a significant boost towards an integrated biosimilars enterprise model.
This integrated approach encompasses complete oversight of value-generation through development and production, AlongSide Value-Realization through distribution and market deparment. “We have an experienced and committed team in the us which is focused strongly on biosimilars. And the fact that we are there now a full integrated biosimilars companymilars Ion with the Payers, The PBMS (Pharmacy Benefit Manners ) And HMO (Health Maintenance Organization) Sector. Brand presence in the global markets. We are building brand biocon and getting a 20% plus market share in the us for some products is significant, “said Kiran mazumdar-shawChairperson of the Biocon Group.
Its subsidiary biocon biologics complete the acquisition of the global biosimilars business of its partner viatris. As a part of the transaction, biocon biologics issued compulsory Basis. It made an upfront cash payment of $ 2 billion to viatris. Biocon Biologics Crossed $ 1 Billion Revenue in FY24.
Biocon Group's Dec Quarter Revenue Rose Rs 3,821 Crore, with performance drive 11%.
(Tagstotranslate) Business News (T) Viatris Acquisition (T) Kiran Mazumdar-Shaw (T) Generics (T) Brand Presence (T) Biosimilars (T) Biocon
Leave a Reply